… The field of oncology is witnessing a paradigm shift in the treatment of lymphomas, fueled by the emergence of…
Browsing: Hodgkin Lymphoma
Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study titled “Results from an Intergroup…
In an interview, Andrew Evens, DO, an expert in hematology and oncology, will discuss a study on predicting progression-free survival…
By: Elizabeth Brem, MD Date: October 06, 2023 Elizabeth Brem, MD, began her talk by addressing some disclosures she had…
By: Allen Wilbanks Date: September 27/2023 Swetha Kambhampati, MD, presented at a conference with gratitude to the organizers and Dr.…
Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of…
iFrame is not supported! Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What…
Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of…
Steven Ansell, MD, PhD, Professor of Medicine at Mayo Clinic. In this video, he speaks about the ASCO Abstract -…
The clinical trial that we are discussing is Echelon-1. This is a study specifically for patients with advanced-stage Hodgkin’s lymphoma…
Kevin R. Krull, Ph.D., Member, St. Jude Faculty, Endowed Chair in Cancer Survivorship at St. Jude Children’s Research Hospital. In…
Survivors of childhood Hodgkin’s Lymphoma have been an unrecognized group for a number of years because they don’t receive direct…
Anita Kumar, MD from Memorial Sloan Kettering Cancer Center speaks about Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly…
Alex F. Herrera, MD of the City of Hope speaks about the ASH 2020 abstract – 472 Consolidation with Nivolumab…
Radhakrishnan Ramchandren, MD Investigator and Chief, Division of Hematology/Oncology from the University of Tennessee Medical Center discusses the ASH 2020…
Miles Prince, MD of Peter MacCallum Cancer Centre discusses the ASH 2020 abstract – The ECHELON-2 Trial: 5-year Results of…
Anna Sureda, MD, Ph.D. of the Blood Cell Barcelona speaks about the ASH 2020 abstract – 2973 Brentuximab Vedotin with…
Mehul Dalal, Ph.D. Takeda Oncology discusses ASH 2020 abstract – 2979 Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing…
John Kuruvilla, MD of the Princess Margaret Cancer Centre and the University of Toronto speaks about ASH 2020 abstract -…
William G. Wierda, MD, Ph.D. – Professor Department of Leukemia, University of Texas MD Anderson Cancer Center speaks about ASH…
John Kuruvilla, MD of the Princess Margaret Cancer Centre and the University of Toronto discusses KEYTRUDA Is the First Anti-PD-1…
Miguel Ferreira, MSc of GlobalData discusses how the Hodgkin’s lymphoma market to suffer with Adcetris patent expiry but benefit from…
Michael Wang, MD @michaelwangmd of @MDAndersonNews discusses KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with…
The utilization of interim positron emission tomography (PET) imaging to guide therapeutic decisions has the potential to further individualize therapy,…
Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses clinical trials testing new drugs on patients with relapsed Hodgkin…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN,…
Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses the dramatic and exciting approach of using CAR T-cells to…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN,…
Treatment of advanced Hodgkin lymphoma has evolved dramatically in the last 10 years, especially with the introduction of PET-response adapted…
At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Wendy Osborne, MBBS (Hons), MRCP,…
The combination of brentuximab vedotin and ESHAP has had positive results when used prior to autologous stem cell transplant in…
Trends in the use of stem cell transplantation in relapsed and refractory Hodgkin lymphoma are currently being studied by the…
Autologous transplant is unsuccessful in ~50% of Hodgkin lymphoma (HL) patients. Here, Stephen Robinson, MBBS, MRCP, MRCPath, PhD, of University…
Joseph M. Connors, MD shares Increase in Toxicity of Two Different Types for ECHELON-1 Trial at AACR 2018
Joseph M. Connors, MD shares No Difference in Overall Survival at AACR 2018
Joseph M. Connors, MD shares FDA Reviewing Details of the Study | Approved Brentuximab at AACR 2018
Joseph M. Connors, MD shares FDA Reviewing Details of the Study | Approved Brentuximab at AACR 2018
Joseph M. Connors, MD shares Trial Established Use of Brentuximab + AVD As Viable Option for Clinicians at AACR 2018
Joseph M. Connors, MD shares Specific Endpoint for the Comparison of the Two Treatments for ECHELON-1 Trial at AACR 2018
Joseph M. Connors, MD shares Results from ECHELON-1 Trial at AACR 2018
Liviu Niculescu, MD PhD, explains Reanalysis of Study in Hodgkin Lymphoma 23% Reduction in Risk of Modified PFS at Annual…